Avalon Pharma (Middle East Pharmaceutical) (4016.SR)

Net assets on the balance sheet as of March 2026 : HK$0.87 Billion

According to Avalon Pharma (Middle East Pharmaceutical)'s latest financial reports the company has HK$0.87 Billion in net assets.
A company’s net assets is the sum of its assets minus the sum of its liabilities.

Avalon Pharma (Middle East Pharmaceutical) - Net assets on balance sheet (from 2023 to 2026)

Net assets by year

Year	Net assets	Change
2025-12-31	$HK$0.86 B	13.42%
2024-12-31	$HK$0.76 B	19.25%
2023-12-31	$HK$0.63 B

What is the market capitalization of a company?

The market capitalization sometimes referred as Marketcap, is the value of a publicly listed company.
In most cases it can be easily calculated by multiplying the share price with the amount of outstanding shares.

DISCLAIMER

CompaniesMarketCap is not associated in any way with CoinMarketCap.com
Stock prices are delayed, the delay can range from a few minutes to several hours.
Company logos are from the CompaniesLogo.com logo database and belong to their respective copyright holders. Companies Marketcap displays them for editorial purposes only.

Contact

For inquiries or if you want to report a problem write to hello@8marketcap.com

Links

- Privacy policy

- Terms and conditions

Avalon Pharma (Middle East Pharmaceutical) (4016.SR) - Net assets